Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Mayawala, Kapil
40  Ergebnisse:
Personensuche X
?
1

Tumor dynamics in patients with solid tumors treated with p..:

Topp, Brian G. ; Channavazzala, Madhav ; Mayawala, Kapil...
Cancer Cell.  41 (2023)  9 - p. 1680-1688.e2 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Assessment of Clinical Response to V937 Oncolytic Virus Aft..:

Parra‐Guillen, Zinnia P. ; Sancho‐Araiz, Aymara ; Mayawala, Kapil...
Clinical Pharmacology & Therapeutics.  114 (2023)  3 - p. 623-632 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Dose Finding in Oncology: What is Impeding Coming of Age?:

Mayawala, Kapil ; de Alwis, Dinesh
Pharmaceutical Research.  39 (2022)  8 - p. 1817-1822 , 2022
Link: https://doi.org/10.1007/..
 
?
4

Correction to: Dose Finding in Oncology: What is Impeding C..:

Mayawala, Kapil ; de Alwis, Dinesh
Pharmaceutical Research.  39 (2022)  6 - p. 1281-1281 , 2022
Link: https://doi.org/10.1007/..
 
?
5

Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for ..:

Li, Tommy R. ; Chatterjee, Manash ; Lala, Mallika...
Clinical Pharmacology & Therapeutics.  110 (2021)  1 - p. 200-209 , 2021
Link: https://doi.org/10.1002/..
 
?
6

Beyond the single average tumor: Understanding IO combinati..:

Kumar, Rukmini ; Thiagarajan, Kannan ; Jagannathan, Lakshmanan...
CPT: Pharmacometrics & Systems Pharmacology.  10 (2021)  7 - p. 684-695 , 2021
Link: https://doi.org/10.1002/..
 
?
7

Experimental Medicine Study to Measure Immune Checkpoint Re..:

Lassman, Michael E. ; Chappell, Derek L. ; McAvoy, Thomas...
Clinical Pharmacology & Therapeutics.  109 (2021)  6 - p. 1575-1582 , 2021
Link: https://doi.org/10.1002/..
 
?
8

Corrigendum to "A six-weekly (Q6W) dosing schedule for pemb..:

Lala, Mallika ; Li, Tommy Ruosi ; de Alwis, Dinesh P....
European Journal of Cancer.  144 (2021)  - p. 400 , 2021
Link: https://doi.org/10.1016/..
 
?
9

Mechanistic Modeling of a Novel Oncolytic Virus, V937, to D..:

Parra-Guillen, Zinnia P. ; Freshwater, Tomoko ; Cao, Youfang...
Frontiers in Pharmacology.  12 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
10

Mechanistic Basis for Maximally Efficacious Dose of Pembrol..:

Mayawala, Kapil ; Nayak, Tapan ; Jain, Lokesh.
Clinical Pharmacology & Therapeutics.  111 (2021)  5 - p. 994-994 , 2021
Link: https://doi.org/10.1002/..
 
?
11

A six-weekly dosing schedule for pembrolizumab in patients ..:

Lala, Mallika ; Li, Tommy Ruosi ; de Alwis, Dinesh P....
European Journal of Cancer.  131 (2020)  - p. 68-75 , 2020
Link: https://doi.org/10.1016/..
 
?
12

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorti..:

Geva, Ravit ; Voskoboynik, Mark ; Dobrenkov, Konstantin...
Cancer.  126 (2020)  22 - p. 4926-4935 , 2020
Link: https://doi.org/10.1002/..
 
?
13

Strategies and Recommendations for Using a Data‐Driven and ..:

Leach, Michael W. ; Clarke, David O. ; Dudal, Sherri...
Clinical Pharmacology & Therapeutics.  109 (2020)  6 - p. 1395-1416 , 2020
Link: https://doi.org/10.1002/..
 
?
14

Immunogenicity of pembrolizumab in patients with advanced t..:

van Vugt, Marianne J. H. ; Stone, Julie A. ; De Greef, "Rik" H. J. M. M....
Journal for ImmunoTherapy of Cancer.  7 (2019)  1 - p. , 2019
Link: https://doi.org/10.1186/..
 
?
15

Clinical outcomes with therapies for previously treated rec..:

Lala, Mallika ; Chirovsky, Diana ; Cheng, Jonathan D..
Oral Oncology.  84 (2018)  - p. 108-120 , 2018
Link: https://doi.org/10.1016/..
 
1-15